DOTHIEPIN HCL
- CAS No.
- 897-15-4
- Chemical Name:
- DOTHIEPIN HCL
- Synonyms
- DOSULEPIN HCL;DOTHIEPIN HYDROCHLORIDE;Dothiepin-d6 HCl;Altapin;Depresym;DOTHIEPIN HCL;dosulepinchloride;dosulepinhydrochloride;prothiadenhydrochloride;Nalidixic Acid Impurity 10
- CBNumber:
- CB0667773
- Molecular Formula:
- C19H22ClNS
- Molecular Weight:
- 331.9
- MDL Number:
- MFCD00941484
- MOL File:
- 897-15-4.mol
- MSDS File:
- SDS
| Melting point | 218-221℃ |
|---|---|
| storage temp. | -20°C |
| solubility | Freely soluble in water, in alcohol and in methylene chloride. |
| CAS DataBase Reference | 897-15-4 |
| FDA UNII | 3H0042311V |
SAFETY
Risk and Safety Statements
| Symbol(GHS) |  GHS07 |
|---|---|
| Signal word | Warning |
| Hazard statements | H302 |
| Precautionary statements | P301+P312+P330 |
| Hazard Codes | F,T,Xn |
| Risk Statements | 11-23/24/25-39/23/24/25-22 |
| Safety Statements | 7-16-36/37-45 |
| RIDADR | 3249 |
| HazardClass | 6.1(b) |
| PackingGroup | III |
DOTHIEPIN HCL price More Price(13)
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| Sigma-Aldrich | D2962000 | Dosulepin hydrochloride European Pharmacopoeia (EP) Reference Standard | 897-15-4 | d2962000 | $152 | 2024-03-01 | Buy |
| TRC | D536508 | DothiepinHydrochloride | 897-15-4 | 5mg | $145 | 2021-12-16 | Buy |
| Biosynth Carbosynth | BD164382 | Dothiepin hydrochloride | 897-15-4 | 10mg | $55 | 2021-12-16 | Buy |
| Biosynth Carbosynth | FD65010 | Dothiepin HCl | 897-15-4 | 50g | $100 | 2021-12-16 | Buy |
| AK Scientific | 3732BB | Dothiepinhydrochloride | 897-15-4 | 10mg | $124 | 2021-12-16 | Buy |
DOTHIEPIN HCL Chemical Properties,Uses,Production
Chemical Properties
White or faintly yellow, crystalline powder.
Uses
Monoamine reuptake inhibitor; tricyclic antidepressant
Uses
Dothiepin Hydrochloride is a tricyclic antidepressant.
Clinical Use
Tricyclic antidepressant
Drug interactions
Potentially hazardous interactions with other drugs
Alcohol: increased sedative effect.
Analgesics: increased risk of CNS toxicity with
tramadol; possibly increased risk of side effects with
nefopam; possibly increased sedative effects with
opioids.
Anti-arrhythmics: increased risk of ventricular
arrhythmias with amiodarone - avoid; increased
risk of ventricular arrhythmias with disopyramide,
dronedarone, flecainide or propafenone - avoid with
dronedarone.
Antibacterials: increased risk of ventricular
arrhythmias with moxifloxacin and possibly
delamanid and telithromycin - avoid with
moxifloxacin.
Anticoagulants: may alter anticoagulant effect of
coumarins.
Antidepressants: enhanced CNS excitation and
hypertension with MAOIs and moclobemide -
avoid; concentration possibly increased with SSRIs;
risk of ventricular arrhythmias with citalopram
and escitalopram - avoid; possible increased risk of
convulsions with vortioxetine.
Antiepileptics: convulsive threshold lowered;
concentration reduced by carbamazepine,
phenobarbital and possibly fosphenytoin, phenytoin
and primidone.
Antimalarials: avoid with artemether/lumefantrine
and piperaquine with artenimol.
Antipsychotics: increased risk of ventricular
arrhythmias especially with droperidol, fluphenazine,
haloperidol, pimozide, risperidone, sulpiride and
zuclopenthixol - avoid; increased antimuscarinic
effects with clozapine and phenothiazines;
concentration increased by antipsychotics
Antivirals: increased risk of ventricular arrhythmias
with saquinavir - avoid; concentration possibly
increased with ritonavir.
Atomoxetine: increased risk of ventricular
arrhythmias and possibly convulsions.
Beta-blockers: increased risk of ventricular
arrhythmias with sotalol.
Clonidine: tricyclics antagonise hypotensive
effect; increased risk of hypertension on clonidine
withdrawal.
Dapoxetine: possible increased risk of serotonergic
effects - avoid
Dopaminergics: avoid use with entacapone; CNS
toxicity reported with selegiline and rasagiline.
Metabolism
Dosulepin hydrochloride is readily absorbed from the gastrointestinal tract, and extensively demethylated by first-pass metabolism in the liver to its primary active metabolite, desmethyldothiepin (also termed northiaden). Paths of metabolism also include S-oxidation. Dosulepin is excreted in the urine, mainly in the form of its metabolites; small amounts are also excreted in the faeces. Elimination half-lives of about 14-24 and 23-46 hours have been reported for dosulepin and its metabolites, respectively. Dose in renal impairment GFR (mL/min) 20-50 Dose as in normal renal function. 10-20 Start with small dose and titrate according to response. <10 Start with small dose and titrate according to response. Dose in patients undergoing renal replacement therapies APD/CAPD Not dialysed. Dose as in GFR<10 mL/ min. HD Not dialysed. Dose as in GFR<10 mL/ min. HDF/High flux Unknown dialysability. Dose as in GFR<10 mL/min. CAV/VVHD Unknown dialysability. Dose as in GFR=10-20 mL/min. Important drug interactions Potentially hazardous interactions with other drugs Alcohol: increased sedative effect. Analgesics: increased risk of CNS toxicity with tramadol; possibly increased risk of side effects with nefopam; possibly increased sedative effects with opioids. Anti-arrhythmics: increased risk of ventricular arrhythmias with amiodarone - avoid; increased risk of ventricular arrhythmias with disopyramide, dronedarone, flecainide or propafenone - avoid with dronedarone. Antibacterials: increased risk of ventricular arrhythmias with moxifloxacin and possibly delamanid and telithromycin - avoid with moxifloxacin. Anticoagulants: may alter anticoagulant effect of coumarins. Antidepressants: enhanced CNS excitation and hypertension with MAOIs and moclobemide - avoid; concentration possibly increased with SSRIs; risk of ventricular arrhythmias with citalopram and escitalopram - avoid; possible increased risk of convulsions with vortioxetine. Antiepileptics: convulsive threshold lowered; concentration reduced by carbamazepine, phenobarbital and possibly fosphenytoin, phenytoin and primidone. Antimalarials: avoid with artemether/lumefantrine and piperaquine with
DOTHIEPIN HCL Preparation Products And Raw materials
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| Hangzhou FandaChem Co.,Ltd. | 008657128800458; +8615858145714 | fandachem@gmail.com | China | 9341 | 55 |
| Hubei Jusheng Technology Co.,Ltd. | 18871490254 | linda@hubeijusheng.com | CHINA | 28180 | 58 |
| Xi'an MC Biotech, Co., Ltd. | 029-89275612 +8618991951683 | mcbio_sales@163.com | China | 2255 | 58 |
| Finetech Industry Limited | +86-27-87465837 +8618971612321 | info@finetechnology-ind.com | China | 9634 | 58 |
| Dayang Chem (Hangzhou) Co.,Ltd. | 571-88938639 +8617705817739 | info@dycnchem.com | CHINA | 52867 | 58 |
| Alfa Chemistry | +1-5166625404 | Info@alfa-chemistry.com | United States | 21317 | 58 |
| PT CHEM GROUP LIMITED | +86-85511178 +86-85511178 | peter68@ptchemgroup.com | China | 35453 | 58 |
| Aladdin Scientific | +1-833-552-7181 | sales@aladdinsci.com | United States | 57511 | 58 |
| S.Z. PhyStandard Bio-Tech. Co., Ltd. | 0755-83725681-603 | China | 4505 | 50 | |
| Clearsynth Labs Limited | +91-22-26355700 | info@clearsynth.com | India | 9685 | 58 |